Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: clinical phase 2 trial
Anaphylm™, Aquestive’s Needleless Sublingual Epinephrine, Takes Another Step Forward
Dave Bloom
-
2023/06/02
Company reports positive topline results from phase 2 study.
Aravax Doses First Patient in Phase 2 Peanut Allergy Clinical Trial
News Wire ~ 3rd Party Press Release
-
2023/06/01
PVX108 does not contain peanut proteins which put patients at risk of serious side effects.
Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy
Dave Bloom
-
2023/03/01
Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting
News Wire ~ 3rd Party Press Release
-
2023/02/28
A unique peanut allergy immunotherapy continues to show promise for children.
Study of Boiled Peanuts Show Promise for Treatment of Peanut Allergy
Dave Bloom
-
2023/01/13
OIT with boiled followed by roasted peanuts appears effective with a favorable safety profile.
Company Completes Enrollment for Phase 2 Trial of “Immune Resetting” Peptide...
News Wire ~ 3rd Party Press Release
-
2023/01/05
Topline data anticipated in Q2 2023.
Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...
News Wire ~ 3rd Party Press Release
-
2022/10/12
Response confirms approach and supports the characterization of their novel drug platform.
Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...
Dave Bloom
-
2022/09/27
The company announced topline results from their EPIPHAST II study.
Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia ...
News Wire ~ 3rd Party Press Release
-
2022/07/21
STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
News Wire ~ 3rd Party Press Release
-
2022/06/16
Phase 2 study continues to show AQST-109 is safe and well tolerated.
1
2
3
Page 1 of 3